ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS
Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. Patients were randomized to receive placebo; 5, 20,...
Main Authors: | J. M. Neutel, W. J. Elliott, J. L. Izzo, C. L. Chen, H. N. Masonson |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2011-04-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1155 |
Similar Items
-
EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
by: Steven G. Chrysant, et al.
Published: (2011-06-01) -
Olmesartan medoxomil for the treatment of hypertension in children and adolescents
by: Volpe M, et al.
Published: (2011-03-01) -
Stability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
by: Lisiane Bajerski, et al.
Published: (2013-01-01) -
Stability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
by: Lisiane Bajerski, et al.
Published: (2013-01-01) -
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: Mason
Published: (2011-06-01)